Life Sciences Drug DevelopmentAndover, MA
DeuteRx is a clinical stage biopharmaceutical company focused on improving racemic small molecule drugs for patients. Numerous drugs are still developed and marketed as racemates because the enantiomers rapidly interconvert. The novel approach of 'deuterium-enabled chiral switching' enables stabilization and characterization of the preferred enantiomer. The lead compound, DRX-065, is currently in Phase 1 clinical trials for adrenoleukodystrophy (ALD) and NASH. DeuteRx was founded in December 2012 as a spin-out company from Deuteria Pharmaceuticals Inc. Deuteria was sold to a major biopharmaceutical company in December 2012.